Aligos Therapeutics Inc. has patented programmed cell death 1 (PDCD1; PD-1; CD279) and/or PD-1 ligand 1 (PD-L1; CD274) and/or PD-1/PD-L1 interaction inhibitors reported to be useful for the treatment of liver cancer (hepatocellular carcinoma) and hepatitis B.